PMID- 36086967
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20220913
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 50
IP  - 5
DP  - 2022
TI  - Zeaxanthin attenuates OVA-induced allergic asthma in mice by regulating the p38 
      MAPK/beta-catenin signaling pathway.
PG  - 75-83
LID - 10.15586/aei.v50i5.664 [doi]
AB  - BACKGROUND: Asthma is a heterogeneous and complex chronic airway disease with a 
      high incidence rate, characterized by chronic airway inflammation. Although the 
      anti-inflammatory effect of zeaxanthin has been demonstrated in various disease 
      models, its explicit role in allergic asthma remains elusive. METHODS: An 
      allergic asthma model was established by ovalbumin (OVA) stimulation in BALB/c 
      nude mice. The pathological examination, collagen deposition and expression of 
      alpha-smooth muscle actin (alpha-SMA) in lung tissues were determined by hematoxylin and 
      eosin (H&E), MASSON and immunofluorescence staining, respectively. Besides, the 
      effect of zeaxanthin on inflammation and oxidative stress was assessed by the 
      enzyme-linked immunosorbent assay (ELISA) and spectrophotometry measure. 
      Moreover, the underlying mechanism was analyzed by detecting the expression of 
      phosphorylated p38 (p-p38), p38, beta-catenin, p-c-Jun N-terminal kinase (p-JNK) and 
      JNK with western blot assays. RESULTS: The distinct infiltration of inflammatory 
      cells was observed in the OVA-induced asthma mice model with significantly 
      increased concentrations of immunoglobulin E (IgE), interleukin-4 (IL-4), IL-5, 
      IL-13 and eotaxin (p<0.001), which were prominently reversed by zeaxanthin 
      treatment (p<0.001). In addition, zeaxanthin treatment decreased the OVA-induced 
      collagen deposition and alpha-SMA expression. A similar inhibitory effect of 
      zeaxanthin on the oxidative stress was also observed in the OVA-induced asthma 
      mice model, as evidenced by the prominent decrease of malondialdehyde (MDA) 
      concentration and the remarkable increase of superoxide dismutase (SOD), 
      glutathione S transferase (GST) and Glutathione (GSH) concentrations (p<0.001). 
      Moreover, zeaxanthin introduction markedly reduced the relative expressions of 
      p-p38/p38, beta-catenin and p-JNK/JNK in the OVA-induced asthma mice model 
      (p<0.001), indicating that zeaxanthin suppressed the p38 mitogen-activated 
      protein kinase (p38 MAPK)/beta-catenin signaling pathway in the OVA-induced asthma 
      mice model. CONCLUSIONS: Zeaxanthin attenuated OVA-induced allergic asthma in 
      mice via modulating the p38 MAPK/beta-catenin signaling pathway.
FAU - Jin, Xiaosheng
AU  - Jin X
AD  - Department of Respiration, Tongde Hospital of Zhejiang Province, Hangzhou, China.
FAU - Jin, Weijing
AU  - Jin W
AD  - Department of Neonatology, Hangzhou Children's Hospital, Hangzhou, China; 
      jinweijing0506@163.com.
FAU - Li, Guoping
AU  - Li G
AD  - Department of Respiration, Tongde Hospital of Zhejiang Province, Hangzhou, China.
FAU - Zheng, Jisheng
AU  - Zheng J
AD  - Department of Respiration, Tongde Hospital of Zhejiang Province, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220901
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Zeaxanthins)
RN  - 0 (beta Catenin)
RN  - 9006-59-1 (Ovalbumin)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
SB  - IM
MH  - Animals
MH  - *Asthma/etiology
MH  - Disease Models, Animal
MH  - Inflammation/complications
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Ovalbumin/adverse effects
MH  - Signal Transduction
MH  - Zeaxanthins/adverse effects
MH  - *beta Catenin/metabolism
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
OTO - NOTNLM
OT  - Asthma
OT  - ovalbumin
OT  - p38 MAPK
OT  - zeaxanthin
OT  - beta-catenin
COIS- The authors state that there are no conflict of interest to disclose.
EDAT- 2022/09/11 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/09/10 06:03
PHST- 2022/05/07 00:00 [received]
PHST- 2022/06/02 00:00 [accepted]
PHST- 2022/09/10 06:03 [entrez]
PHST- 2022/09/11 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
AID - 10.15586/aei.v50i5.664 [doi]
PST - epublish
SO  - Allergol Immunopathol (Madr). 2022 Sep 1;50(5):75-83. doi: 
      10.15586/aei.v50i5.664. eCollection 2022.